Sign Up For Live
Surfing The NASH Tsunami Podcast now includes Live Audience attendance during recordings. We record Monday afternoons EST, with invites sent out on Fridays. Our host Roger Green will invite you into the epsiode to ask your questions and to address your feedback regarding anything and everything in Fatty Liver Disease. Our usual Surfers will also be there too… each week… every episode!

Ep 37 – Monday at TLMdX 2020 from AASLD: Getting Better at Diagnostics and Drugs, Not Education

Mary Rinella joins the Surfers for a final day of AASLD 2020 reviewing focusing equally on lessons in drug development and the crying need for social and dietary education, particularly for parents and children.

The Surfers spend the final day of AASLD 2020 looking at two very different sets of issues.

Issue 1: challenges proving efficacy in F2 populations, particularly in terms of fibrosis.

Issue 2: social burdens of poor dietary choices around the world, particularly given how developing PNAFLD (pediatric non-alcoholic fatty liver disease) can create a metabolic burden that can last a lifetime.

In the end, the group remained optimistic about the explosion of knowledge around drugs and diagnostics for NASH and NAFLD but troubled by the lack of social policy, awareness or education around these issues.

Dr. Stephen Harrison — LP23

RESOLVE-IT PHASE 3 TRIAL OF ELAFIBRANOR IN NASH: FINAL RESULTS OF THE3 WEEK 72 ITNERIM SURROGATE EFFICACY ANALYSIS

Louise Campbell MSc AP — 141

DIET RELATED MORTALITYARY AMONG NONALCOHOLIC FATTY LIVER DISEASE (NAFLD): DATA FROM THE GLOBAL BURDEN OF DISEASE (GBD) 2017

Roger Green — 

L03 – ALDAFERMIN  (NGM282) PRODUCES GREATER ANTI-FIBROTIC RESPONSE IN PATIENTS WITH  NONALCOHOLIC STREATOHEPATITIS AND ADVANCED FIBROSIS

&

0143
ONSET OF OBESITY-RELATED PEDIATRIC NONALCOHOLIC FATTY LIVER DISEASE (PNAFLD) DURING PREPUBERTAL GROWTH EXACERBATES HEPATIC INFLAMMATION AND MITOCHONDRIAL DNA DEPLETION TO ACCELERATE LIVER INJURY

Mary E. Rinella, MD. — 010

EFFICACY AND SAFETY OF SUBCUTANEOUS SEMAGLUTIDE ONCE-DAILY VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS

Request Transcript of This Episode
Request Transcript
First
Last

Stay In Touch with Surfing NASH

Stay In Touch
  • Name
  • Email & NPI
  • Country
  • Institution & Profession